Baylor researchers develop better colorectal cancer animal model, find p16 gene drives colorectal cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A team, led by researchers at Baylor College of Medicine, reported in the Journal of Experimental & Clinical Cancer Research that silencing the gene p16, even though the DNA itself does not change, can drive colorectal cancer progression in animal models. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login